摘要
目的:研究利培酮与阿立哌唑治疗精神分裂症的经济学效果。方法:将112例住院精神分裂症患者随机分为利培酮组(58例)与阿立哌唑组(54例),用阳性症状和阴性症状量表(PANSS)评分减少量进行效果评价,以副反应量表(TESS)评分评定不良反应,并进行成本-效果分析。结果:利培酮组与阿立哌唑组人均成本分别为4 111.38、3 340.43元,PANSS评分减少量分别为41.8±7.2、42.3±6.9,成本-效果比分别为7 040.03、5 227.59。结论:阿立哌唑治疗精神分裂症较经济。
OBJECTIVE： To compare the pharmacoeconomic efficacy between risperidone and aripiprazole in treating schizophrenia.METHODS：A total of 112 inpatients with schizophrenia were randomly assigned to receive risperidone（n = 58） or aripiprazole group（n = 54） .The effects were evaluated using Positive and Negative Symptoms Scale（PANSS） ; the adverse effects were evaluated using Treatment Emergent Symptom Scale（TESS） .The cost - effectiveness analysis was performed.RESULTS： The per capita costs for risperidone group and aripiprazole group were 4 111.38yuan and 3 340.43yuan, respectively; the reduction of PANSS scores were 41.8 ± 7.2 and 42.3 ±6.9, respectively and the cost - effectiveness ratios were 7 040.03 and 5 227.59,respectively .CONCLUSION ：Aripiprazole is more economical than risperidone in the treatment of schizophrenia.
出处
《中国药房》
CAS
CSCD
北大核心
2007年第26期2004-2005,共2页
China Pharmacy
关键词
精神分裂症
利培酮
阿立哌唑
成本-效果分析
Schizophrenia
Risperidone
Aripiprazole
Cost - effectiveness analysis
